Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/52570
Title: Imagining the severe asthma decision trees of the future.
Authors: Bourdin A.;Bardin P. ;Chanez P.
Monash Health Department(s): Respiratory and Sleep Medicine
Institution: (Bourdin) Departement de Pneumologie et Addictologie, PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, Montpellier, France
(Bardin) Monash Lung and Sleep Allergy Immunology, Monash Hospital, Monash Health and University, Hudson Institute, Melbourne, VIC, Australia
(Chanez) APHM, Clinique des bronches allergies et sommeil, Marseille, France
(Chanez) Aix Marseille Univ, INSERM U1263, INRA 1260 (C2VN), Marseille, France
Issue Date: 30-Sep-2024
Copyright year: 2024
Publisher: Taylor and Francis Ltd.
Place of publication: United Kingdom
Publication information: Expert Review of Respiratory Medicine. 18(8) (pp 561-567), 2024. Date of Publication: 2024.
Journal: Expert Review of Respiratory Medicine
Abstract: Introduction: There are no validated decision-making algorithms concerning severe asthma (SA) management. Future risks are crucial factors and can be derived from SA trajectories. Areas covered: The future severe asthma-decision trees should revisit current knowledge and gaps. A focused literature search has been conducted. Expert opinion: Asthma severity is currently defined a priori, thereby precluding a role for early interventions aiming to prevent outcomes such as exacerbations (systemic corticosteroids exposure) and lung function decline. Asthma 'at-risk' might represent the ultimate paradigm but merits longitudinal studies considering modern interventions. Real exacerbations, severe airway hyperresponsiveness, excessive T2-related biomarkers, noxious environments and patient behaviors, harms of OCS and high-doses inhaled corticosteroids (ICS), and low adherence-to-effectiveness ratios of ICS-containing inhalers are predictors of future risks. New tools such as imaging, genetic, and epigenetic signatures should be used. Logical and numerical artificial intelligence may be used to generate a consistent risk score. A pragmatic definition of response to treatments will allow development of a validated and applicable algorithm. Biologics have the best potential to minimize the risks, but cost remains an issue. We propose a simplified six-step algorithm for decision-making that is ultimately aiming to achieve asthma remission.Copyright © 2024 Informa UK Limited, trading as Taylor & Francis Group.
DOI: http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1080/17476348.2024.2390987
PubMed URL: 39120156 [https://www.ncbi.nlm.nih.gov/pubmed/?term=39120156]
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/52570
Type: Article
Subjects: artificial intelligence
drug megadose
epigenetics
genetics
lung function
respiratory tract allergy
severe asthma
Type of Clinical Study or Trial: Review article (e.g. literature review, narrative review)
Appears in Collections:Articles

Show full item record

Page view(s)

4
checked on Oct 23, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.